MFS Multimarket Income Trust rebrands as Aberdeen Multi-Market Income Fund

MFS Multimarket Income Trust (NYSE: MMT) completed a reorganization absorbing two affiliated funds and transferred investment management to abrdn Inc. on June 22, 2026, before the opening of the New York Stock Exchange.

MFS Intermediate High Income Fund (CIF) and MFS Charter Income Trust (MCR) were merged into MMT. CIF shareholders received 0.36109198 MMT shares for each CIF share held, while MCR shareholders received 1.33352869 MMT shares per MCR share. Net asset values used for the exchange were calculated at the close of business on June 18, 2026. MMT's NAV per share stood at $4.8898, compared with $1.7657 for CIF and $6.5207 for MCR.

Simultaneous with the reorganization, MFS Investment Management was replaced by abrdn Inc. as the fund's investment adviser. The fund was renamed Aberdeen Multi-Market Income Fund, though its ticker symbol MMT and CUSIP number 552737108 remain unchanged, and it continues to trade on the NYSE.

The fund's prior board of trustees resigned, replaced by five trustees elected by shareholders on May 18, 2026: Todd Reit, Nancy Yao, C. William Maher, Gordon Baird, and Christian Pittard.

Aberdeen's Global Fixed Income team will manage the fund, led by Jonathan Mondillo, Global Head of Fixed Income; Siddharth Dahiya, Global Head of Emerging Market Debt; Anthony Merola, Senior Investment Manager; and George Westervelt, Head of Global High Yield.

The fund's primary investment objective of seeking high current income while also considering capital appreciation remains unchanged. The fund plans to transition its portfolio to an average investment-grade credit quality over the next six months. No other changes to investment policies or strategies are currently anticipated.

According to the press release, Aberdeen had approximately $506 billion in assets under management as of March 31, 2026, and managed 27 closed-end funds totaling $25.6 billion in assets.

You May Also Be Interested In

• Baxter raises tender offer cap to $600M for senior notes
• Trump highlights ibogaine development push, Psyence BioMed responds
• BT Brands posts Q2 profit, cuts costs as restaurant sales dip